Anti-Lox-1 [AbAb01LOX1]

Description:

Recombinant monoclonal antibody to Lox-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display clone AbAb01LOX1.

Clone Name:

AbAb01LOX1

Published Application(s):

ELISA

Published Species Reactivity:

Human

Products based on this clone:

{{heading}}

Please Select

Ab03429-23.0 Anti-Lox-1 [AbAb01LOX1]
Human
Rabbit IgG
Purified
Ships in 5-6 weeks

Ab03429-3.0 Anti-Lox-1 [AbAb01LOX1]
Human
Mouse IgG2b
Purified
Ships in 5-6 weeks

Ab03429-3.3 Anti-Lox-1 [AbAb01LOX1]
Human
Mouse IgG2b
Fc Silent™
Purified
Ships in 5-6 weeks

Ab03429-10.0 Anti-Lox-1 [AbAb01LOX1]
Human
Human IgG1
Purified
Ships in 5-6 weeks

Ab03429-10.3 Anti-Lox-1 [AbAb01LOX1]
Human
Human IgG1
Fc Silent™
Purified
Ships in 5-6 weeks

UniProt Accession Number of Target Protein: P78380

Alternative Name(s) of Target: LOX1; hLOX-1; OLR1; CLEC8A; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; Lectin-type oxidized LDL receptor 1; Oxidized low-density lipoprotein receptor 1 soluble form
Immunogen: The original antibody was isolated from a human scFv phage display library by panning against human Lox-1.

Specificity: This antibody binds oxidized low density lipoprotein (ox-LDL), which is a receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis.

Application Notes: This antibody can be used for the detection of Lox-1, which is a marker for early diagnosis of atherosclerosis. The binding characterization of this antibody was done using ELISA. The binding affinity of this antibody for human Lox-1 was determined using Bio-layer Interferometry (BLI) and it was reported that the binding affinity of this scFv antibody was Kd= 6.69 nM (CN107216390).

Antibody first published in: PMID: